FeesSafety
Pluang+

Tempus AI reports 23% revenue growth and $193M from new data deals over 5 years

Company Fundamentals
19 Nov 2026, 13:35 WIB
The Motley Fool Team
View Source
Bullish
Tempus AI reports 23% revenue growth and $193M from new data deals over 5 years

Tempus AI reported a 23% year-over-year revenue increase to $411.5 million in Q3 2026, driven by rising test prices and multiyear biopharma licensing agreements expected to generate $193 million over five years. The company also anticipates an $80 million boost in oncology test pricing in 2027 due to FDA approvals. Positive adjusted EBITDA of $25.6 million reflects operational scale and gross profit growth. Tempus aims to sustain long-term growth by reinvesting in AI and clinical data to maintain leadership in oncology diagnostics.

Tempus AI holds a market cap of $11.57 billion as of Nov 19, 2026, 13:51 WIB, reflecting its significant presence in the oncology diagnostics sector. The stock price on Pluang is USD 64.50, showing a 1.38% increase in the last day, while trading volume reached 6,141,978 shares. Investor interest appears strong with 95% of Pluang order activity being buys, indicating confidence in Tempus AI's growth prospects.

More News (TEM)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App